For the quarter ending 2025-09-30, ISCO had $46K increase in cash & cash equivalents over the period. $46K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 57 | -127 |
| Stock-based compensation | 63 | 161 |
| Depreciation and amortization | 56 | 109 |
| Non-cash operating lease expense | 79 | 150 |
| Interest expense on related party note payable | 35 | 75 |
| Change in inventory reserve | -26 | 55 |
| Accounts receivable | -86 | 43 |
| Inventories | -12 | 470 |
| Prepaid expenses and other current assets | -107 | 146 |
| Accounts payable | -132 | 211 |
| Accrued liabilities | -199 | 124 |
| Operating lease liabilities | -89 | -172 |
| Net cash (used in) provided by operating activities | 49 | -73 |
| Purchases of property and equipment | 3 | 37 |
| Net cash used in investing activities | -3 | -37 |
| Payments on related party note payable | 0 | 200 |
| Net cash used in financing activities | 0 | -200 |
| Net decrease in cash | 46 | -310 |
| Cash and cash equivalents at beginning of period | 1,230 | - |
| Cash and cash equivalents at end of period | 966 | - |
International Stem Cell CORP (ISCO)
International Stem Cell CORP (ISCO)